Previous Close | 3.6400 |
Open | 3.5800 |
Bid | 3.1200 x 900 |
Ask | 3.5600 x 3000 |
Day's Range | 3.4037 - 3.5800 |
52 Week Range | 2.0600 - 12.6100 |
Volume | |
Avg. Volume | 79,924 |
Market Cap | 252.105M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0700 |
Earnings Date | Apr 26, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.49 |
Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on vaccinations to treat a
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significantDemographic and baseline biomarker data indicate a confluence of factors which may have caused the study to have lower than expected statistical powerAll mutation carriers may continue to receive crenez
A look at the shareholders of AC Immune SA ( NASDAQ:ACIU ) can tell us which group is most powerful. Institutions will...